الفهرس 
صفحة العنوانOnly 14 pages are availabe for public view
 |  | from | 309 |  |  |
| | | from | 309 | | |
Abstract
ABSTRACT
Objective: Breast cancer (BC) is one of the most widespread health-threatening diseases among women worldwide, and it is one of the major causes of mortality among cancer patients. In 2021, 2.3 million women were diagnosed with BC, with 685,000 fatalities worldwide. Women diagnosed at an earlier stage have a five-year survival rate of more than 90%, while women diagnosed at the most advanced stage have about 15%. So, we need more sensitive new molecular non-invasive biomarkers for early BC diagnosis. This study was aimed to evaluate the diagnostic efficacy of serum expressions of (miR-106a-5p and miR-195), and RAF-1 levels. In addition, investigate their correlation with other conventional biomarkers such as CEA and CA15.3 as well as different clinicopathological features of BC patients. Methods: Fifty early diagnosed BC women and thirty control women with no malignancy were involved in this study. Expressions of miR-106a-5p and miR-195 were measured by real-time PCR while RAF-1 serum levels were determined by ELISA. Results: The study results demonstrated that both miR-106a-5p and miR-195 were up-regulated in BC patients with fold change 3.63, 1.47; respectively. Serum level of RAF-1 was significantly